No difference in the 3-year LRC rate was observed between SABR and surgery (risk ratio = 0.95; 95% CI = [0.82, 1.09]; P = 0.453). Subgroup analysis was conducted on the basis of surgical procedures. In the subgroup analysis, SABR was found to yield significantly shorter OS than lobectomy (hazard ratio = 1.68; 95% CI = [1.09, 2.60]; P = 0.018), whereas SABR was comparable to sublobar resection in terms of 3-year survival rate, OS and 3-year LRC rate. Our meta-analysis found that lobectomy yielded better survival outcomes than SABR, whereas SABR yielded comparable rates when compared with sublobar resection. Lobectomy is still the preferred method for treating earlystage NSCLC. Well-designed and multicentred randomized controlled trials with large sample sizes, however, are needed to confirm and update our conclusions.
INTRODUCTION
Lung cancer is the leading cause of cancer deaths in the world [1] , and non-small-cell lung cancer (NSCLC) accounts for 75-85% of all lung cancers. With the development of medical screening methods, more and more cases of early-stage NSCLC are being uncovered [2] . Lobectomy with lymph node dissection has traditionally been regarded as the standard treatment for patients with early-stage NSCLC [3] . Clinical trials comparing sublobar resection, including wedge resection and segmentectomy, to lobectomy in treating early-stage NSCLC [4] are now ongoing.
Stereotactic ablative radiotherapy (SABR), also called stereotactic body radiotherapy (SBRT), a highly precise radiotherapy using an external focused beam under the guidance of high-resolution imaging techniques to target well-defined tumours [5] , has been intensively investigated in the treatment of early-stage NSCLC. SABR was initially used with patients with early-stage NSCLC but with contraindications for surgery, such as severe comorbidities and poor pulmonary function, or with those who refused surgery.
Since related clinical trials have demonstrated that SABR is associated with excellent overall survival (OS), high rates of local tumour control, moderate treatment-related morbidity and low toxicity [6] , investigators are beginning to explore its role in treating operable patients with early-stage NSCLC [7] . Several retrospective studies [8] [9] [10] [11] [12] were conducted to compare the efficacy of SABR with that of surgery in treating stage I NSCLC, but their results were controversial. Some concluded that SABR yielded OS comparable with that of surgery [9, 10, 12] , whereas others argued that SABR showed significantly lower OS than surgery [8, 11] . Two systematic reviews [5, 13] pointed out that the shortand medium-term OS of SABR were equivalent to those of surgery for stage I NSCLC. However, a meta-analysis [14] published in 2014 (containing six studies with 864 patients) demonstrated a superior 3-year survival rate in patients treated with surgery compared with SABR. To date, the roles that SABR and surgery have played in treating early-stage NSCLC have not yet been well defined. One reason is that nearly all of the analyses mentioned previously [5, [8] [9] [10] [11] [12] 14] compared SABR with 'surgery', but 'surgery' actually comprises lobectomy, sublobar resection (wedge resection and segmentectomy) and even pneumonectomy. As we know, lobectomy and sublobar resection (wedge resection and segmentectomy) are quite different surgical procedures imposing quite different impacts on the prognosis of NSCLC. Recent studies [15] [16] [17] have demonstrated that lobectomy with lymph node dissection offers a more optimal prognosis for earlystage NSCLC than sublobar resection. Therefore, the clinical value of a comparison without subgroup analysis is weakened. The other reason is that no randomized controlled trials (RCTs) on this topic have been completed, and because of the limited sample sizes, previous clinical studies concerning subgroup analysis failed to make a definite conclusion [18] [19] [20] [21] [22] [23] [24] . Therefore, whether SABR is comparable to surgery (lobectomy or sublobar resection) in treating stage I NSCLC remains unknown. In our current metaanalysis, we tried to include all of those up-to-date qualified studies to draw a conclusion about the choice for treating stage I NSCLC. To our knowledge, this is the most comprehensive metaanalysis with the largest qualified sample size that focuses not only on a comparison between SABR and surgery but also on subgroup analysis.
MATERIALS AND METHODS

Search strategies
Systematic computerized searches of the PubMed, Embase, Cochrane Library databases and Google scholar as well as the American Society of Clinical Oncology annual meeting for reports dated through 31 December 2015 were performed using the following search terms: 'stereotactic ablative radiotherapy or SABR', 'stereotactic body radiotherapy or SBRT', 'surgery' and 'non-small-cell lung cancer or NSCLC'. The full search strategy is provided in Supplementary Table S1. All reference lists from the trials selected by electronic searching were scanned to further identify relevant trials.
Study selections
The following criteria were used for study inclusion: (i) either completed RCTs or propensity score matching observational studies compared SABR or SBRT versus surgery in treating patients with clinical stage I NSCLC; (ii) sufficient data could be obtained for 3-year survival rates, hazard ratios (HRs) of SABR to surgery for OS or 3-year loco-regional control (LRC) rates and (iii) the most recent or completed study was chosen if the studies were based on overlapping patients. The exclusion criteria were as follows: (i) papers that were not randomized or well matched; (ii) papers without any relevant data that could be extracted for analysis; (iii) papers that were not published in English and (iv) case reports, abstracts, conference reports, reviews and experiments.
Data extraction and quality assessment
Two authors (Han-Yu Deng and Yun-Cang Wang) independently extracted data from the studies and compared the results. Discrepancies were resolved by adjudication by a third author (Peng-Zhi Ni) to avoid bias. Data were carefully retrieved from full articles using a standardized data collection form. The following data were collected from each study: first author, year of publication, number of patients, age, study design and follow-up. The outcomes included 3-year survival rate, OS and 3-year LRC rate. The Jadad scale [25] was used for quality assessment of RCTs. The quality assessment and risk-of-bias analysis of observational studies were evaluated by the Newcastle-Ottawa Scale [26] , which comprises three factors: patient selection, comparability of the study groups and assessment of outcome. A score of 0-9 (allocated as stars) was assigned to each study, and a high-quality study was defined as a study with quality scores > _7 ( Table 1 ). The name of the first author and the year of publication of the article were used for identification.
Statistical analysis
We conducted one meta-analysis of overall results (SABR versus surgery) and two subgroup meta-analyses (one meta-analysis of SABR versus lobectomy and a second meta-analysis of SABR versus sublobar resection). All analyses were performed according to PRISMA guidelines [27] by using the STATA 12.0 package (StataCorp, College Station, TX, USA). For dichotomous data, such as 3-year survival rate and 3-year LRC rate, risk ratio (RR) with 95% confidence interval (CI) was used, and the 3-year survival rate and the 3-year LRC rate were extracted directly from the text or from a Kaplan-Meier curve reported in the individual studies. An HR of SABR compared with surgery with a 95% CI was used to compare the OS of each group. When the HR was not directly reported from those original articles, it was estimated as demonstrated by Parmar et al. [28] . For each study, the between-study heterogeneity was assessed using v 2 -based Q statistics and the I 2 test. Random effects models were used because of the high heterogeneity of the studies (P < 0.1 or I 2 > 50%). Otherwise, fixed effects models were used. Subgroup analysis was conducted on the basis of different surgical methods. Sensitivity analysis was performed by sequential removal of each study. A funnel plot was used to estimate potential publication bias. Asymmetry of the funnel plot was tested by Begg's test and Egger's test [29] . Statistical significance was set at P < 0.05
RESULTS
Description of studies
A flow chart of our study is shown in Fig. 1 . No RCTs but 12 observational studies [8] [9] [10] [11] [12] [18] [19] [20] [21] [22] [23] [24] (cohort studies) with a total of 13 598 patients that satisfied the criteria were included in our meta-analysis. The main data extracted from these included studies are listed in Table 1 . Nearly all of those patients were clinically staged by computed tomographic and positron emission tomographic scanning or mediastinoscopy. All patients in the studies were clinically stage I NSCLC except one patient [20] who was stage II. All of those studies used the propensity score matching method to include eligible patients in their analysis. Patients were propensity matched on age, gender, performance score and comorbidity scores. The range of doses in the SABR group was 32-60 Gy in 2-12 fractions. In the surgery group, operation included lobectomy, sublobar resection and pneumonectomy. Data of survival outcomes for analysis consisted of the 3-year survival rate, the OS and the 3-year LRC rate. The 3-year survival rate could be obtained from 10 studies, the HR of OS could be obtained or estimated from 11 studies and the 3-year LRC rate could be obtained from four studies. Data about the comparison of SABR and lobectomy could be obtained from six studies, whereas data about the comparison of SABR with sublobar resection could be obtained from four studies (Table 2) .
Quality assessment and risk of bias analysis
Because no qualified RCTs are included in our meta-analysis, the quality assessment and risk-of-bias analyses of the included studies were evaluated by the Newcastle-Ottawa Scale, which was used for non-RCTs. Quality assessments of the included studies are listed in Table 1 . Eight studies [9] [10] [11] [12] [20] [21] [22] [23] were ranked as studies of high quality, whereas the other four studies [8, 18, 19, 24] were not. The studies of relatively low quality introduced a risk of bias.
Meta-analysis of overall analysis
Ten studies representing 12 836 patients reported a 3-year survival rate for patients with stage I NSCLC receiving either SABR or surgery. The pooled 3-year survival rates for patients treated with SABR and surgery were 47.7% and 68.1%, respectively. Patients treated with SABR had a significantly lower 3-year survival rate than patients treated with surgery (random effects model: RR = 0.78; 95% CI = [0.68, 0.90]; P = 0.001; I 2 = 87.2%) ( Fig.  2A ). Eleven studies (1746 patients) reported the OS of patients with stage I NSCLC receiving either SABR or surgery. Patients treated with SABR yielded significantly shorter OS than patients treated with surgery (random effects model: HR = 1.60; 95% CI = [1.24, 2.06]; P < 0.001; I 2 = 61.5%) (Fig. 2B) . Only four studies reported the 3-year LRC rate of each group. There was no difference between patients treated with SABR and those with surgery in the 3-year LRC rate (83.9% and 86.8%, respectively) (random effects model: RR = 0.95; 95% CI = [0.82, 1.09]; P = 0.453; I 2 = 75.1%) (Fig. 2C) . Obvious heterogeneities were observed in the analysis of overall results. Therefore, we conducted two subgroup analyses based on surgical procedures (one meta-analysis of SABR versus lobectomy and a second meta-analysis of SABR versus sublobar resection).
Meta-analysis of stereotactic ablative radiotherapy versus lobectomy
Six studies with a total of 1184 patients were included. The pooled 3-year survival rates for patients treated with SABR and Those studies with the same author and year of publication were extracted from the same article comparing SABR with lobectomy and SABR with sublobar resection individually; therefore, they shared the same identification code.
lobectomy were 61.3% and 70.6%, respectively. There was no statistical difference in the 3-year survival rate for both groups (random effects model: RR = 0.85; 95% CI = [0.71, 1.01]; P = 0.069; I 2 = 73.4%) ( Fig. 2A) . However, patients treated with SABR yielded significantly shorter OS times than patients treated with lobectomy (random effects model: HR = 1.69; 95% CI = [1.09, 2.60]; P = 0.018; I 2 = 62.8%) (Fig. 2B ). There was no significant difference between SABR and lobectomy for the 3-year LRC rate (84.9% and 86.1%, respectively) (random effects model: RR = 0.97; 95% CI = [0.83, 1.14]; P = 0.746; I 2 = 77.2%) (Fig. 2C ). Those HRs for overall survival were estimated as demonstrated by Parmar et al. [28] . d Those studies with the same author and year of publication were extracted from the same article comparing SABR with lobectomy and SABR with sublobar resection individually; therefore, they shared the same identification code.
Meta-analysis of stereotactic ablative radiotherapy versus sublobar resection
Four studies with a total of 964 patients were included. The pooled 3-year survival rates for patients treated with SABR and sublobar resection were 57.0% and 61.1%, respectively. There was no statistical difference in the 3-year survival rate for both groups (random effects model: RR = 0.83; 95% CI = [0.62, 1.11]; P = 0.219; I 2 = 67.6%) ( Fig. 2A) . No significant difference in OS was observed between SABR and sublobar resection (random effects model: HR = 1.52; 95% CI = [0.88, 2.63]; P = 0.133; I 2 = 70.3%). There was also no significant difference in the 3-year LRC rate between them (75.9% and 93.1%, respectively) (random effects model: RR = 0.81; 95% CI = [0.65, 1.02]; P = 0.078) (Fig. 3C) .
Sensitivity analysis and publication bias
We conducted a sensitivity analysis by sequentially removing each study to evaluate the stability of our results based on the 3-year survival rate and OS, and it showed that sequential removal of each study did not change the survival outcomes of the primary analysis (Fig. 3 ). Publication bias was tested, and an asymmetrical appearance on a funnel plot analysis was observed based on the 3-year survival rate. However, there was no statistical significance in Egger's test (overall analysis: Begg's test: P = 0.086; Egger's test: P = 0.100) (Fig. 4) , which may only indicate a possible publication bias.
DISCUSSION
Lobectomy is widely recommended as the standard treatment for patients with stage I NSCLC who can tolerate it. Recently, sublobar resection (including wedge resection and segmentectomy) has been suggested as an alternative surgical treatment for early-stage NSCLC [30] . Although it is too early to draw any conclusions, many studies [15] [16] [17] support the observation that lobectomy results in more optimal prognosis than sublobar resection. Recently, several studies [9] [10] [11] [18] [19] [20] [21] have focused on comparing the efficacy of surgery with that of SABR in treating stage I NSCLC. In 2014, a meta-analysis [14] reported the clinical significance of surgery in treating early-stage NSCLC compared with SABR, but the power of its conclusion was limited due to the relatively small sample size (six studies with 864 patients) and lack of subgroup analysis. Six more clinical trials [8, 12, [22] [23] [24] 31] have been published, one of which has drawn worldwide attention by evoking intensive discussion on whether surgery could be replaced by SABR [31] . Therefore, for the purpose of drawing a comprehensive and clearer picture of the roles SABR and surgery performed in treating stage I NSCLC, we conducted this meta-analysis involving 12 studies and 13 598 patients. We focused not only on comparing SABR and surgery but also on subgroup analysis.
According to the data we collected, the 3-year survival rate, the 3-year LRC rate and OS were chosen as the essential survival outcomes. Our meta-analysis uncovered a significantly lower 3-year survival rate (47.7% vs 68.1%, RR = 0.78; 95% CI = [0.68, 0.90]; P = 0.001) and shorter OS (HR = 1.60; 95% CI = [1.24, 2.06]; P < 0.001) for patients treated with SABR compared with those treated with surgery (combo of lobectomy, sublobar resection and even pneumonectomy), whereas comparable 3-year LRC rates were observed between SABR and surgery (RR = 0.95; 95% CI = [0.82, 1.09]; P = 0.453). In the subgroup analysis, we found that lobectomy yielded a significantly longer OS (HR = 1.69; 95% CI = [1.09, 2.60]; P = 0.018) and tended to yield a higher 3-year survival rate (RR = 0.85; 95% CI = [0.71, 1.01]; P = 0.069) than SABR and a 3-year LRC rate comparable to SABR. We also found that Forest plot of (A) 3-year survival rate, (B) OS and (C) 3-year locoregional control rate in patients treated with SABR compared with surgery. Subgroup analysis was conducted on the basis of surgical procedures (lobectomy and sublobar resection). Note: Those studies with the same author and year of publication were extracted from the same article comparing SABR with lobectomy and SABR with sublobar resection individually; therefore, they shared the same identification code. sublobar resection yielded an OS, a 3-year survival rate and a 3-year LRC rate comparable to those with SABR. Our results might explain, at least to some extent, why different studies have drawn controversial conclusions in comparing SABR with surgery in treating early-stage NSCLC [9] [10] [11] [18] [19] [20] [21] . When a study mixed sublobar resection with lobectomy together in one group of 'surgery', the efficacy of the 'surgery' was actually a compromised efficacy that was positively improved by the efficacy of the lobectomy and was negatively affected by sublobar resection. For example, some studies concluded that SABR could yield OS comparable to that of surgery [9, 10, 12] , whereas a recent retrospective study that compared SABR with surgery in treating early-stage NSCLC (enrolling more than 10 000 patients from National Cancer Database) found that patients treated with surgery had significantly longer OS times than those treated with SABR [8] . Our meta-analysis also demonstrated a comparable 3-year LRC rate not only between SABR and surgery but also in the subgroup analysis. We therefore believe that SABR offers good short-term control of early-stage NSCLC but that for the long-term prognosis, surgery, especially lobectomy, is still the standard, not to mention the fact that clinical stage I NSCLC has a risk of containing occult lymph node metastases [32] . A newly published study [33] reported that SABR had a 3-year survival rate of 59.9% in patients with stage I NSCLC, but it is well known that stage I NSCLC has a 5-year survival rate up to 80% after lobectomy [15, 34] . Yu et al. [35] reported that for patients with a long life expectancy, SABR yielded significantly greater overall mortality rates as well as a trend towards greater lung cancerrelated mortality than surgery. Moreover, SABR was less costeffective than lobectomy [24] .
Chang's pooled analysis [31] comparing SABR with lobectomy in treating early-stage NSCLC was excluded from our meta-analysis because its statistical methods and conclusions contain serious challenges [36] ; we also noticed problems in Chang's study. However, these academic conflicts emphasize the need for larger RCTs with a more rational design that includes subgroup comparisons [37] .
Our meta-analysis has several limitations. First, our metaanalysis was based upon retrospective cohort studies, which may reduce the statistical power due to lack of completed RCTs. In addition, not all of these studies were ranked as studies of high quality, which introduces a potential bias. Second, even though we conducted subgroup analyses, we still observed heterogeneity in our meta-analysis, which may be produced by the differences in SABR doses and tumour locations as well as by the status of the patients included in the studies. Besides, we included wedge resection and segmentectomy together in the group of those receiving sublobar resection, but whether wedge resection and segmentectomy yielded similar prognoses in patients with early-stage NSCLC is still debatable. Third, a possible publication bias (P = 0.086) was observed in our meta-analysis. Moreover, we could not obtain the HR for comparing OS directly from some studies [9-11, 19, 21-23] ; therefore, we estimated the HRs for these studies on the basis of the 3-year or 5-year OS as previously described [28] . Still, some survival outcomes could not be extracted from certain enrolled studies, especially for the analysis of the 3-year LRC rate and the cancer-specific survival rate. Finally, some of the included studies reported their results with a relatively short follow-up time. Therefore, RCTs with longer follow-up times are needed to precisely compare SABR (especially with a high biologically effective dose) with surgery (separating lobectomy, wedge resection and segmentectomy) in treating stage I NSCLC.
CONCLUSION
Lobectomy yielded significantly superior long-term survival outcomes compared with SABR, whereas SABR yielded a local control rate comparable to that of lobectomy as well as sublobar resection. Lobectomy remains the best option for patients with stage I NSCLC who can tolerate it, whereas for patients who cannot tolerate lobectomy, SABR is an alternative treatment with a prognosis comparable to that of sublobar resection.
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